English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Long-term survival in Diffuse Intrinsic Pontine Glioma (DIPG) is very rare. The purpose of this report is to detail the early (1988) use of IV Antineoplaston therapy (ANP {A-10 + AS2-1}) and its efficacy in DIPG while presenting the 27.7-year survival of a 36-year-old patient treated with ANP for progressive DIPG. Methods: The patient presented in this manuscript was enrolled in BT-3, a Phase II protocol utilizing IV Antineoplastons A10 and AS2-1 (ANP). Tumor response was measured by bi-monthly MRIs of the brain. All surviving patients were followed for more than three years. Results: This patient presented to the Burzynski Clinic (BC) with an anaplastic (high-grade) astrocytoma of the pons (DIPG) with resultant paralysis of the right side of the face, diplopia, decrease in strength of the left upper extremity and decreased sensation involving the left upper extremity and left thigh. The patient was experiencing poor balance with difficulty walking, and had dysphagia, right ear hearing loss, memory loss, and headaches. Following ANP, she developed a persistent Complete Response (CR). In BT-3, ANP was administered to a total of 20 patients diagnosed with astrocytomas. Seventeen patients were classified as high grade while three patients were classified as low grade. Four patients achieved a CR, two patients achieved a Partial Response (PR), ten patients had stable disease (SD), and four patients developed progressive disease (PD). Subsequently, one patient having SD achieved a PR. Two patients with SD in BT-3 were subsequently enrolled in a Phase II clinical trial that utilized continuous infusion of higher dose ANP. Both of these patients then developed a CR. Conclusion: BT-3 led to further Phase II clinical studies, which involved a more aggressive use of ANP, including continuous infusions of higher dose A10 and AS2-1 utilizing ambulatory infusion pumps. In addition, there was an increased utilization of ANP in a variety of lowand highgrade brain tumors under the Burzynski Research Institute’s (BRI’s) IND # 43,742.

international journal of radiology and imaging technology

Long-Term Survival (27.7 Years) Following IV Antineoplaston Therapy (ANP) in a 36-Year-Old Female with a Progressive Diffuse Intrinsic Pontine Glioma (DIPG)